2284 results found | searching for "team"

First Previous 6 7 8 9 10 11 12 13 14 15 Next Last 
  • jameshebrew
  • The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035, claims Roots Analysis An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries. Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings. Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding. Key Market Insights Currently, around 120 needlestick safety injection devices are available in the market More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections. Over 50 companies claim to develop needlestick safety injection devices, worldwide Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%). Partnership activity within this field has grown significantly between 2020 and 2022 Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions. Over USD 260 million has been invested by both private and public investors, since 2016 Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain. Close to 20 global events were organized in the past couple of years in this industry Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries. More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018 Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes. North America and Europe are anticipated to capture more than 75% of the market by 2035 Growth in this domain is anticipated to be primarily driven by the rising cases of needlestick injuries amongst the healthcare workers. The Asia-Pacific needlestick safety injection devices market currently accounts for more than 20% of the global market. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/needlestick-safety-market/request-sample.html Key Questions Answered  Who are the leading needlestick safety injection devices developers?  Which are the popular types of safety injection devices available in this market?  What are the key challenges faced by stakeholders engaged in the development of needlestick safety injection devices?  What types of partnership models are commonly being adopted by stakeholders in this industry?  How has the intellectual property landscape of needlestick safety injection devices developers evolved over the years?  Which factors are likely to influence the evolution of this market?  How is the current and future market opportunity likely to be distributed across key market segments? The research also includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.  B. Braun  BD  Gerresheimer  HTL-STREFA  Nipro Europe Group Companies  SOL-MILLENNIUM Medical Group For additional details, please visit https://www.rootsanalysis.com/reports/needlestick-safety-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • mtecscaf
  • MTEC has been trading since 2008 and is a family run business.They offer a range of access solutions to both residential and commercial clients.Their goal is to provide every customer with an outstanding experience, from concept to completion.They offer a friendly and highly professional scaffolding service.They specialise in everything related to scaffolding, which refers to the temporary structure on the outside of a building, used by construction workers whilst building, repairing, or cleaning the building. Scaffolding is typically made from wooden planks and metal poles.For more information about scaffolding hire, that we provide, please feel free to get in touch with our dedicated team by completing our online contact form, or by emailing us at enquiries@mtecscaffolding.com.
  • Loadoutroom
  • Get an introduction to gear, tips and advice on the best guns, EDC knives, jump boots, and a whole lot more at Loadout Room. Get the low-down on top gear, professional reviews and find out where to buy it. We aims to provide the most relevant and exciting articles, reviews and news from our team of professional outdoor enthusiasts. Website: https://loadoutroom.com/
  • jameshebrew
  • The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development. London Roots Analysis has announced the addition of “Gene Therapy Market (5th Edition), 2022-2035” report to its list of offerings. Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type I) and Libmeldy™ (for metachromatic leukodystrophy), this domain has garnered significant interest in the medical community. Moreover, considering the promising trial results of pipeline candidates, notable players have made investments to support product development and commercialization efforts. An analysis of the investments made at various stages, such as seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other equity offerings, by gene therapy companies that are engaged. An elaborate discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages and limitations of currently available gene delivery vectors. Key Market Insights Over 1,150 gene therapies are currently being developed across different stages Apart from 11 approved products, most of the aforementioned therapies (70%) are in early stages of development (preclinical / discovery), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of the clinical stage candidates target oncological diseases. Further, majority of such therapies (66%) use adenovirus vectors as molecular carriers. More than 250 companies claim to be engaged in the development of gene therapies, globally In the past decade, over 160 companies have been established in this domain. Of the total, 60% of the players are small firms. In addition, majority (62%) of these gene therapy developers are based in North America, primarily in the US. 290+ clinical trials evaluating gene therapies have been registered, worldwide Of the total number of trials registered during the period 2015-2020, close to 10% have already been completed, while 56% are presently recruiting patients. Further, presently, around 55% of the trials are evaluating therapy candidates in phase II studies. USD 8.5+ billion has been invested by both private and public investors, since 2015 The maximum funding amount was raised through secondary offerings (40%), venture capital (28%) and IPOs (16%), during the period 2015-2022. Interestingly, majority (77%) of the funding instances were reported by players based in North America. Over 5,800 patents have been filed / published related to gene therapies, since 2017 Around 90% of the total number of patent applications were related to gene therapies, while the remaining were focused on gene editing-based therapies. Further, majority of the patent assignees were industry players. However, it is worth mentioning that the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 19%), over the past few years. Merger and acquisition activity in this market has grown at a CAGR of 22%, during 2015-2021 It is worth mentioning that, across most of the instances (43%) both the acquirer and the acquired company were based in North America. Moreover, majority of the acquisitions (26%) were focused on providing access to novel platform / technology, followed by acquisitions undertaken for therapeutic area consolidation (24%) and drug class consolidation (24%). The overall market is anticipated to grow at a CAGR of over 18%, during the period 2022-2035 Gene therapies based on gene augmentation currently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. North America (primarily the US) is expected to capture 60% of the market share by 2035, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/268/request-sample.html Key Questions Answered  Who are the key industry players engaged in the development of gene therapies?  How many gene therapy candidates are currently in the development pipeline? Which key disease indications are targeted by such products?  Which types of vectors are most commonly used for effective delivery of gene therapies?  What are the key regulatory requirements for gene therapy approval, across various geographies?  Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of the development cycle?  What are the different pricing models and reimbursement strategies currently being adopted for gene therapies?  What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?  Who are the key CMOs / CDMOs engaged in supplying viral / plasmid vectors for gene therapy development?  What are the key value drivers of the merger and acquisition activity in the gene therapy industry?  Who are the key stakeholders that have actively made investments in the gene therapy domain?  Which are the most active trial sites (in terms of number of clinical studies being conducted) for gene therapies?  How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the gene therapy market has been analyzed across the following segments:  Type of Therapy  Gene augmentation  Immunotherapy  Oncolytic viral therapy  Others  Type of Gene Delivery Method Used  Ex vivo  In vivo  Type of Vector Used  Adeno-associated virus  Adenovirus  Herpes simplex virus  Lentivirus  Non-viral vectors  Retrovirus  Others  Target Therapeutic Areas  Cardiovascular diseases  Dermatological diseases  Genetic diseases  Hematological diseases  Infectious diseases  Metabolic diseases  Muscle-related diseases  Oncological diseases  Ophthalmic diseases  Others  Route of Administration  Intraarticular  Intracerebral  Intracoronary  Intradermal  Intralesional  Intramuscular  Intrapleural  Intrathecal  Intratumoral  Intravenous  Intravesical  Intravitreal  Subretinal  Topical  Others  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration and recent developments (if available).  Abeona Therapeutics  AGTC  AnGes  Biogen  BioMarin Pharmaceutical  bluebird bio  Castle Creek Biosciences  CG Oncology  FerGene  GenSight Biologics  Helixmith  Holostem Terapie Avanzate  Inovio Pharmaceuticals  Kolon TissueGene  Krystal Biotech  Lysogene  Neurophth Therapeutics  Orchard Therapeutics  Pfizer  PTC Therapeutics  REGENXBIO  Sangamo Therapeutics  Spark Therapeutics  VBL Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • RichestSoft
  • Webflow Developer for Hire https://richestsoft.com/hire-webflow-developer With webflow, you can create responsive websites without any need for coding or programming. If you're looking for a webflow developer for hire? Get in touch with RichestSoft. As a trusted Webflow CMS development company, we cover a range of services ranging from custom web design & development to CMS development services. We have the best team of Webflow CMS developers and the largest pool of Webflow CMS expertise in the world. Talk to Webflow Experts!
  • benmarkny
  • Nowadays, millions of QuickBooks user encounters problems related to QB Payroll unable to update. This problem generally appears with an QuickBooks error code 15106. This software has never failed to amaze their users with its highly notable & beneficial features. But there always some limitation and restriction in QB tool, one of such issue is QB error 15106. There is no such problem in QuickBooks which cannot be resolve – Error 15106 is one of them. In this blog, we have discussed about QuickBooks error code 15106 and it’s causes. However, you can save your precious time and efforts by calling QuickBooks error support team performing the below given technical steps: Read more: https://www.hostdocket.com/quickbooks-payroll-update-error-15106/ [more]
  • m_booker
  • Pharmacy Management Software Development. Any software system is as good as it is used and with the right inputs from your side, we are certain that the expert team of Ardas can meet and exceed all your requirements. We strive to deliver the right fit to match your needs for today while keeping enough scope in the system to handle the increased pressures of tomorrow. https://ardas-it.com/pharmacy-management-software-development [more]
  • watsjosephine
  • How can I speak to someone at Allegiant Air? Do you want to speak to someone at allegiant air services you want for passengers, our team really very flexible connect with representative through live chat, emails, media easily grab the best offers. https://www.fareodeal.com/blog/how-can-i-speak-to-someone-at-allegiant-air [more]
  • jameshebrew
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products. Key Questions Answered  Who are the leading players offering services for the development of companion diagnostics?  Which are the key geographies where companion diagnostics development service providers are located?  Which analytical techniques are used by the service providers engaged companion diagnostics development services market?  Who are the leading companion diagnostics developers?  Which biomarkers are most commonly targeted by the marketed products / investigational programs?  Which partnership models are commonly adopted by stakeholders offering companion diagnostics development services?  Which drug developers are most likely to partner with the service providers to seek their expertise?  What are the key value drivers of the merger and acquisition activity within companion diagnostics development services market?  Which biomarker-focused targeted drugs developed by big pharmaceutical companies are likely to be administered with companion diagnostics?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the companion diagnostics development services market has been analyzed across the following segments:  Type of Service Offered  Feasibility Studies  Assay Development  Analytical Validation  Clinical Validation  Manufacturing  Type of Technique Used  NGS  PCR  ICH / ISH  Liquid Biopsy  Others  Therapeutic Areas  Oncological  Non-oncological  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:  Mike Klein (Chief Executive Officer, Genomenon)  Mark Kiel (Founder and Chief Scientific Officer, Genomenon)  Candace Chapman (Vice President of Marketing, Genomenon)  Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations)  Paul Kortschak (Former Senior Vice President, Novodiax)  Pablo Ortiz (Chief Executive officer, OWL Metabolomics)  Lawrence Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories) The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, and an informed future outlook.  Almac Diagnostic Services  BGI Genomics  Biocartis  Cerba Research  Geneuity Clinical Research Services  Interpace Biosciences  Labcorp (formerly known as Covance)  MEDICAL & BIOLOGICAL LABORATORIES (MBL)  MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)  MLM Medical Labs  Novogene  Q2 Solutions  Quest Diagnostics  ResearchDx For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • saramartingamio
  • Fantasy Cricket Website Developer Insta Gamio, the best Fantasy cricket website development company offers robust fantasy cricket software and a website with unique features. Our team of proficient Fantasy Cricket Website Developers can quickly grasp your website idea and convert it into a feasible product. Our custom solutions ensure to meet the exact requirements of the clients. https://instagamio.com/fantasy-cricket-app-development [more]
First Previous 6 7 8 9 10 11 12 13 14 15 Next Last